Nanobiotix Finalizes $99.9M Global Offering to Fund Development Programs

summarizeSummary

Nanobiotix completed a $99.9 million global offering of ordinary shares and pre-funded warrants, securing significant capital to fund its development programs and extend its cash runway into early 2028.

check_boxKey Events

• Global Offering Finalized

  Nanobiotix finalized a global offering, raising approximately $99.9 million through the sale of 2,184,662 ordinary shares (including ADSs) and 345,099 pre-funded warrants, with an option for underwriters to purchase an additional 33,805 ADSs.

• Pricing Details

  The ADSs were priced at $38.98, representing a ~5% discount to the current market price of $41.01. Each pre-funded warrant was priced at €33.57 (approximately $38.94) with an exercise price of €0.03.

• Dilution and Capital Runway

  The offering is dilutive, potentially increasing outstanding shares by approximately 5.3%. The net proceeds of up to $93.8 million are expected to extend the company's cash runway into early 2028, supporting critical R&D.

• Use of Proceeds

  Proceeds will be used to accelerate development programs, including JNJ-1900 (NBTXR3) and Nanoprimer platforms, and for general corporate purposes.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of the global offering, previously announced on May 21, 2026. Nanobiotix successfully raised approximately $99.9 million through the sale of ordinary shares and pre-funded warrants. While dilutive for existing shareholders, this capital raise is crucial for the company, extending its cash runway into early 2028 and funding the acceleration of its JNJ-1900 (NBTXR3) and Nanoprimer development programs. The offering was priced at a modest discount to the current market price, indicating reasonable market demand, especially following recent positive clinical trial data.